Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat.
In addition to changes in body temperature and other metabolic and physiological responses corresponding to immune activation, pyrogens can induce profound behavioral changes referred to collectively as sickness behavior. One feature of sickness behavior, sometimes reported in clinical settings, but rarely exposed to experimental analysis, is depressed cognitive functioning. The present series of five experiments sought to demonstrate the existence of specific cognitive deficits in rats, independently of any confounding performance effects of pyrogen injections. The behavioral task used, called autoshaping, consisted of presenting hungry Wistar rats with a stimulus (introduction of a retractable lever) that predicted food delivery. Control rats quickly learned to press the lever, although this response does not influence the probability of food delivery. When pyrogens (250 micrograms/kg lipopolysaccharide, 4 micrograms/rat interleukin-1 beta, or 300 mg/rat yeast) were injected to rats during acquisition of this task, they severely disrupted acquisition while the pyrogen was active. The same treatments were, however, without effect on performance when injected later, when performance had stabilized. It is argued that these results demonstrate specific, performance-independent effects of pyrogens on the cognitive processes needed for the acquisition of this task. The results are discussed in terms of the relationship between these effects and the cytokines induced in the brain by pyrogens, and in terms of the exact nature of the cognitive process likely to be affected.
Aubert
A
A
Laboratoire de Neurobiologie Intégrative, INSERM U.394, Bordeaux, France.
Vega
C
C
Dantzer
R
R
Goodall
G
G
D000818:Animals; D001070:Appetitive Behavior / Q000187:drug effects / Q000502:physiology; D003072:Cognition Disorders / Q000139:chemically induced*; D003216:Conditioning, Operant / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004731:Endotoxins / Q000633:toxicity; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007375:Interleukin-1 / Q000633:toxicity*; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D009181:Mycoses / Q000276:immunology / Q000523:psychology*; D011597:Psychomotor Performance / Q000187:drug effects; D011749:Pyrogens / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects; D011994:Recombinant Proteins / Q000633:toxicity; D012441:Saccharomyces cerevisiae; D012803:Sick Role
D004731:Endotoxins; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011749:Pyrogens; D011994:Recombinant Proteins; C044101:endotoxin, Escherichia coli